Literature DB >> 24974453

[Bacterial meningitis caused by beta-lactamase-negative, ampicillin-resistant nontypeable Haemophilus influenzae in a 1-year-old girl: a case report].

Katsuaki Abe, Tadashi Hoshino, Naoko Imuta, Junichiro Nishi, Naruhiko Ishiwada.   

Abstract

We present herein the case report of bacterial meningitis caused by nontypeable Haemophilus influenzae (NTHi) in a 1-year-7-month-old girl with no medically significant history. NTHi from cerebrospinal fluid (CSF) was the beta-lactamase non-producing ampicillin resistant strain (BLNAR). Some beta-lactams were administrated, but fever was prolonged. Finally, rifampicin seemed to be effective. In NTHi, compared with H. influenzae type b (Hib), the prevalence of BLNAR is high. Hence, complicated cases may increase in the near future if the use of the Hib vaccine becomes widespread, and meningitis caused by NTHi increases. It may be necessary to consider combination therapy or use of non-beta-lactams that have a different antimicrobial mechanism from beta-lactams. PCR analysis revealed the possibility that the CSF isolate lacked the P5 protein gene. Though deficiency of P5 fimbriae is known to reduce the affinity of NTHi for the human respiratory epithelium, determining whether P5 deficient NTHi induced meningitis will require further study.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24974453     DOI: 10.11150/kansenshogakuzasshi.88.291

Source DB:  PubMed          Journal:  Kansenshogaku Zasshi        ISSN: 0387-5911


  2 in total

1.  Beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b meningitis in partially immunized immunocompetent child: a case report.

Authors:  Majid Ali Qureshi; Imran Asad; Adeel Chaudhary; Walid Abuhammour
Journal:  J Med Case Rep       Date:  2021-08-18

2.  No development of ciprofloxacin resistance in the Haemophilus species associated with pneumonia over a 10-year study.

Authors:  Josef Yayan; Beniam Ghebremedhin; Kurt Rasche
Journal:  BMC Infect Dis       Date:  2015-11-13       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.